NuCana PLC (NCNA) Now Covered by Cowen and Company
Separately, Jefferies Group LLC started coverage on NuCana PLC in a report on Monday. They set a “buy” rating on the stock.
NuCana PLC (NASDAQ NCNA) opened at 14.08 on Monday. NuCana PLC has a 12-month low of $13.05 and a 12-month high of $19.95. The stock has a 50 day moving average price of $16.06 and a 200-day moving average price of $16.06. The stock’s market capitalization is $447.90 million.
COPYRIGHT VIOLATION WARNING: “NuCana PLC (NCNA) Now Covered by Cowen and Company” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/10/23/nucana-plc-ncna-now-covered-by-cowen-and-company.html.
About NuCana PLC
NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.
Receive News & Stock Ratings for NuCana PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana PLC and related stocks with our FREE daily email newsletter.